Services that help ensure Hemophilia Patients access to Helixate FS

FactorPlus: Start a connection to treating hemophilia A

With FactorPlus, the Helixate FS free trial program, patients can try rFVIII treatment for hemophilia A at no cost. The features and benefits of Helixate FS may make it the right choice for patients living an active lifestyle.

After signing up for FactorPlus, patients will be eligible to receive 6 doses, or up to 20,000 IU, of Helixate FS for treating hemophilia A.

Click here or call 1-866-767-4883 to learn more about FactorPlus or gain access to an enrollment form.

CSL Behring Patient Assistance Program

The Patient Assistance Program provides medically necessary therapies, including hemophilia therapy A, to qualified patients who are uninsured, underinsured, or for those individuals who cannot afford their prescribed therapy.

Through this program, affordable therapy is offered to qualified patients who need assistance. The CSL Behring Patient Assistance Program:

Covers medically necessary therapies
Is available to qualified patients who are uninsured, underinsured, or unable to afford their prescription therapy

Call 1-800-676-4266 (Monday through Friday, 8:00 am to 5:00 pm ET) for more information or to receive an enrollment form, or click here for more information on the program.

CSL Behring Assurance^SM

The CSL Behring Assurance Program is designed to ensure that people who rely on eligible CSL Behring recombinant and plasma-derived therapies can continue to receive these vital treatments even if they experience a lapse in third-party, private health insurance.

This program helps prevent gaps in treatment. CSL Behring Assurance:

Ensures that people who rely on Helixate FS, a hemophilia A therapy, can continue to receive this vital treatment even if they experience a gap in their third-party, private insurance coverage*
Allows patients to build a reserve of up to a total of 1 year’s worth of complimentary product

To enroll in CSL Behring Assurance, or for more information, contact us at 1-866-415-2164 or visit the program website at www.CSLBehringAssurance.com.

Insurance and reimbursement assistance

The CSL Behring Department of Reimbursement Services is staffed with representatives experienced in issues pertaining to insurance obstacles facing patients, and who have an impressive track record of successfully assisting providers, patients, and third-party payers for over 10 years.

Click here for information about reimbursement issues, or contact the CSL Behring Reimbursement Answerline at 1-800-676-4266 (Monday through Friday, 8 am to 5 pm ET).

For more information about programs and services offered by CSL Behring, call our Consumer Affairs Center at 1-888-508-6978.

Next: FactorPlus Trial Program »

Important Safety Information

Helixate^® FS, Antihemophilic Factor (Recombinant), is a recombinant factor VIII treatment indicated for the control and prevention of bleeding episodes and peri-operative management in adults and children (0-16 years) with hemophilia A. Helixate^® FS is also indicated for routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with hemophilia A with no preexisting joint damage.

The most serious adverse reactions are systemic hypersensitivity reactions and the development of high-titer inhibitors necessitating alternative treatments to antihemophilic factor. The most common adverse reactions observed in clinical trials were inhibitor formation in previously untreated or minimally treated patients, skin-associated hypersensitivity reactions, infusion site reactions, and central venous access device (CVAD) line-associated infections.

Helixate^® FS is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including mouse or hamster proteins.

Please see the full prescribing information.